Table 2 Mechanisms of ferroptosis in HCC associated with sorafenib resistance
From: Ferroptosis: insight into the treatment of hepatocellular carcinoma
Factors | Mechanism | Reference |
|---|---|---|
EZH2 | Epigenetic regulation of TFR2 | [93] |
FASN | Binding to HIF1α and subsequently enhancing transcription of SLC7A11 | [94] |
DUSP4 | Modulating the intricate iron metabolism | [95] |
DAZAP1 | Regulating SLC7A11 transcription | [98] |
ABCC5 | Stabilizing SLC7A11 protein, increasing intracellular GSH content, reducing lipid peroxidation accumulation, and activating PI3K/AKT/NRF2 axis | [99] |
MT-1G | A novel transcriptional target of NRF2, inhibiting lipid peroxidation | [101] |
MiR-23a-3p | Inhibiting cellular iron accumulation and lipid peroxidation | [102] |
IGF-2BP3 | Reading NRF2 mRNA’s m6A modification | [103] |
LncRNA HCG18 | Silencing lncRNA HCG18 regulated GPX4-mediated ferroptosis by sponging miR-450B-5P to reduce the degree of sorafenib resistance | [105] |
LncRNA DUXAP8 | Promoting the palmitoylation of SLC7A11 and preventing its lysosomal degradation, thereby enhancing the action of SLC7A11 | [106] |
FNDC5 | Promoting the nuclear translocation pathway of NRF2 by activating PI3K/AKT, enhancing intracellular antioxidant capacity | [107] |